(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy...
Stats | |
---|---|
今日成交量 | 62 539.00 |
平均成交量 | 193 680 |
市值 | 39.01M |
EPS | $0.0500 ( 2024-03-12 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.44 |
ATR14 | $0.00900 (0.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Wood Susan Alyson | Buy | 13 044 | Director Stock Option (right to buy) |
2024-04-01 | Patel Rakesh | Buy | 22 154 | Director Stock Option (right to buy) |
2024-04-01 | Doyle Michael John | Buy | 9 874 | Director Stock Option (right to buy) |
2024-04-01 | Hricak Hedvig | Buy | 5 415 | Director Stock Option (right to buy) |
2024-04-01 | Sassine Andy | Buy | 25 259 | Director Stock Option (right to buy) |
INSIDER POWER |
---|
96.00 |
Last 93 transactions |
Buy: 2 731 076 | Sell: 491 820 |
音量 相关性
ICAD Inc 相关性 - 货币/商品
ICAD Inc 财务报表
Annual | 2023 |
营收: | $17.32M |
毛利润: | $14.54M (83.94 %) |
EPS: | $-0.290 |
FY | 2023 |
营收: | $17.32M |
毛利润: | $14.54M (83.94 %) |
EPS: | $-0.290 |
FY | 2022 |
营收: | $27.94M |
毛利润: | $19.81M (70.90 %) |
EPS: | $-0.540 |
FY | 2021 |
营收: | $33.64M |
毛利润: | $24.24M (72.07 %) |
EPS: | $-0.450 |
Financial Reports:
No articles found.
ICAD Inc
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。